Previous 10 | Next 10 |
JERSEY CITY, N.J., June 23, 2022 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX ), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced the initiation and first patient enrolled in a new Phase...
Regulatory submission for the label extension is supported by positive data from the pivotal Phase 3 CANDLE study in which ibrexafungerp successfully achieved statistically significant superiority over placebo for the primary and key secondary study endpoints. If approved, BREXAFE...
JERSEY CITY, N.J., May 20, 2022 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX ), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced that Marco Taglietti, President and Chief Executive Offic...
SCYNEXIS, Inc. (SCYX) Q1 2022 Earnings Conference Call May 12, 2022, 8:30 AM ET Company Participants Marco Taglietti – President and Chief Executive Officer Christine Coyne – Chief Commercial Officer Dr. David Angulo – Chief Medical Officer Lawrence Hoffman – Inter...
SCYNEXIS press release (NASDAQ:SCYX): Q1 GAAP EPS of -$0.17. Revenue of $0.7M (-65.0% Y/Y). Cash and cash equivalents totaled approximately $95.2 million on March 31, 2022, compared to $104.5 million in cash and cash equivalents on December 31, 2021. Based upon its current operating plan, SCY...
BREXAFEMME ® (ibrexafungerp tablets), launched in September 2021 for the treatment of vulvovaginal candidiasis (VVC), achieved almost 4,000 prescriptions with net revenues of $0.7 million in Q1 2022. Expansion of the labeling to include prevention of recurrent VVC is anticipated ...
SCYNEXIS (NASDAQ:SCYX) is scheduled to announce Q1 earnings results on Thursday, May 12th, before market open. The consensus EPS Estimate is -$0.78 (-239.1% Y/Y) and the consensus Revenue Estimate is $1.09M (-45.5% Y/Y). Over the last 3 months, EPS estimates have seen 1 upward revision and 1 ...
AADI,ACHR,ACTG,ADN,AEG,OTCPK:ALIZF,ALT,AMTX,OTCPK:ARNGF,ARQQ,ATY,BAM,BGRY,BKKT,BT,CAMT,CASI,CORR,CPG,CYBR,CYXT,DAVA,DCBO,DRIO,EMAN,EURN,GENI,HIMX,OTCPK:HNHAF,HUT,IS,KNOP,KT,LQDA,MGIC,OTCPK:MKGAF,ML,MOGO,MTNB,NETI,NICE,OTCPK:NSANY,NVMI,ORTX,PCT,OTCPK:PEYUF,OTCQX:QTRHF,RDCM,OTCPK:RWEOY,SCYX,SFL...
Data show that of the FURI study patients with refractory or relapsed vulvovaginal candidiasis (VVC) treated with ibrexafungerp, 71.4% had successful clinical outcomes. Ibrexafungerp demonstrated positive results in difficult-to-treat VVC patients with severe fungal infections who...
JERSEY CITY, N.J., May 05, 2022 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX ), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced it will host a conference call and live webcast at 8:30 a...
News, Short Squeeze, Breakout and More Instantly...
JERSEY CITY, N.J., July 23, 2024 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced that it will receive a $10 million development milestone payment un...